Abstract
Cold air hyperventilation challenge (CAHC) has been shown to induce bronchoconstriction in asthmatics. We investigated whether terfenadine, a non-sedating H1 antihistamine, had a protective effect against CAHC. Twelve mild-moderate asthmatics, sensitive to both methacholine and CAHC, underwent a double-blind 3-way crossover study of terfenadine at doses of 0, 120, and 240 mg. For four hours after administration of the study drug, pulmonary responses were measured, followed by a CAHC. There was a significant improvement in pulmonary function on the 120-mg and 240-mg days. The percent drop in FEV1 to CAHC was determined by comparing the pre-challenge baseline to the challenge responses. There was a significant attenuation in the FEV1 fall immediately after challenge on active drug days, but it was not sustained. Terfenadine appears to have an attenuating effect against CAHC-induced bronchoconstriction.
| Original language | English |
|---|---|
| Pages (from-to) | 299-301 |
| Number of pages | 3 |
| Journal | Annals of Allergy |
| Volume | 62 |
| Issue number | 4 |
| State | Published - 1989 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
Cite this
Effect of terfenadine on cold air-induced bronchospasm. / Bewtra, Againdra K.; Hopp, R. J.; Nair, N. M.; Townley, R. G.
In: Annals of Allergy, Vol. 62, No. 4, 1989, p. 299-301.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effect of terfenadine on cold air-induced bronchospasm
AU - Bewtra, Againdra K.
AU - Hopp, R. J.
AU - Nair, N. M.
AU - Townley, R. G.
PY - 1989
Y1 - 1989
N2 - Cold air hyperventilation challenge (CAHC) has been shown to induce bronchoconstriction in asthmatics. We investigated whether terfenadine, a non-sedating H1 antihistamine, had a protective effect against CAHC. Twelve mild-moderate asthmatics, sensitive to both methacholine and CAHC, underwent a double-blind 3-way crossover study of terfenadine at doses of 0, 120, and 240 mg. For four hours after administration of the study drug, pulmonary responses were measured, followed by a CAHC. There was a significant improvement in pulmonary function on the 120-mg and 240-mg days. The percent drop in FEV1 to CAHC was determined by comparing the pre-challenge baseline to the challenge responses. There was a significant attenuation in the FEV1 fall immediately after challenge on active drug days, but it was not sustained. Terfenadine appears to have an attenuating effect against CAHC-induced bronchoconstriction.
AB - Cold air hyperventilation challenge (CAHC) has been shown to induce bronchoconstriction in asthmatics. We investigated whether terfenadine, a non-sedating H1 antihistamine, had a protective effect against CAHC. Twelve mild-moderate asthmatics, sensitive to both methacholine and CAHC, underwent a double-blind 3-way crossover study of terfenadine at doses of 0, 120, and 240 mg. For four hours after administration of the study drug, pulmonary responses were measured, followed by a CAHC. There was a significant improvement in pulmonary function on the 120-mg and 240-mg days. The percent drop in FEV1 to CAHC was determined by comparing the pre-challenge baseline to the challenge responses. There was a significant attenuation in the FEV1 fall immediately after challenge on active drug days, but it was not sustained. Terfenadine appears to have an attenuating effect against CAHC-induced bronchoconstriction.
UR - http://www.scopus.com/inward/record.url?scp=0024594273&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024594273&partnerID=8YFLogxK
M3 - Article
C2 - 2565097
AN - SCOPUS:0024594273
VL - 62
SP - 299
EP - 301
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
SN - 1081-1206
IS - 4
ER -